002773.SHE Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Market cap
- CNY 17.9B
- P/E
- 19.0x
- P/B
- 1.84x
- ROE
- 11.1%
- Dividend yield
- 3.10%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002773.SHE undervalued?
Graham number002773.SHE trades 24.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chengdu Kanghong Pharmaceuticals Group Co Ltd fundamental analysis
No fundamental analysis for Chengdu Kanghong Pharmaceuticals Group Co Ltd yet.
Chengdu Kanghong Pharmaceuticals Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices in China. It develops medicines for ophthalmic, neuropsychiatric, and others. The company was founded in 1996 and is headquartered in Chengdu, China.
Full company profileChengdu Kanghong Pharmaceuticals Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chengdu Kanghong Pharmaceuticals Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.54B | 2.79B | 2.92B | 3.26B | 3.30B | 3.61B | 3.39B | 3.96B | 4.45B | 4.59B | 4.23B |
| Gross Profit | 2.30B | 2.52B | 2.69B | 2.99B | 2.97B | 3.25B | 3.00B | 3.52B | 3.98B | 4.12B | 3.75B |
| Operating Income | 551M | 788M | 796M | 821M | -512M | 355M | 1.02B | 1.26B | 1.38B | 1.30B | 1.21B |
| EBITDA | 581M | 748M | 722M | 784M | -529M | 554M | 1.02B | 1.32B | 1.46B | 1.53B | 1.21B |
| Net Income | 497M | 644M | 695M | 718M | -270M | 421M | 897M | 1.04B | 1.19B | 1.16B | 1.05B |
| EPS | 0.57 | 0.73 | 0.80 | 0.82 | -0.29 | 0.46 | 0.98 | 1.14 | 1.30 | 1.26 | 1.13 |
| Balance Sheet | |||||||||||
| Total Assets | 3.76B | 4.59B | 5.19B | 5.83B | 7.00B | 6.96B | 7.72B | 8.53B | 9.34B | 9.92B | 10.1B |
| Total Liabilities | 853M | 1.04B | 1.11B | 1.21B | 1.25B | 851M | 814M | 718M | 695M | 645M | 663M |
| Shareholders' Equity | 2.90B | 3.54B | 4.08B | 4.62B | 5.76B | 6.09B | 6.90B | 7.80B | 8.65B | 9.30B | 9.43B |
| Cash & Short-term Investments | 2.65B | 3.10B | 2.71B | 2.28B | 3.33B | 3.14B | 3.69B | 4.70B | 5.69B | 6.44B | 3.43B |
| Total Debt | 191M | 396M | 342M | 278M | 1.06M | 4.43M | 3.27M | 1.48M | 3.47M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 846M | 767M | 351M | 812M | 273M | 494M | 925M | 1.22B | 1.41B | 1.50B | - |
| Capital Expenditure | 170M | 313M | 458M | 963M | 617M | 569M | 355M | 139M | 159M | 262M | 301M |
| Free Cash Flow | 676M | 454M | -108M | -151M | -344M | -75.3M | 570M | 1.08B | 1.25B | 1.24B | 782M |
| Ratios | |||||||||||
| ROE | 17.1% | 18.2% | 17.0% | 15.5% | -4.7% | 6.9% | 13.0% | 13.4% | 13.8% | 12.5% | 11.1% |
| ROA | 13.2% | 14.0% | 13.4% | 12.3% | -3.9% | 6.1% | 11.6% | 12.2% | 12.8% | 11.7% | 10.4% |
| Net Profit Margin | 19.6% | 23.1% | 23.8% | 22.0% | -8.2% | 11.7% | 26.5% | 26.4% | 26.8% | 25.4% | 24.7% |
| Debt to Equity | 0.07x | 0.11x | 0.08x | 0.06x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chengdu Kanghong Pharmaceuticals Group Co Ltd dividends
- Dividend yield
- 3.10%
- Forward dividend
- 0.70 CNY
- Payout ratio
- 47.5%
- Ex-dividend date
- Jun 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 553M | 0.60 | 47.5% |
| 2024 | CNY 349M | 0.38 | 29.3% |
| 2023 | CNY 138M | 0.15 | 13.2% |
| 2022 | CNY 91.9M | 0.10 | 10.3% |
| 2021 | CNY 91.9M | 0.10 | 21.8% |
| 2020 | CNY 245M | 0.27 | - |
| 2019 | CNY 188M | 0.22 | 26.2% |
| 2018 | CNY 189M | 0.22 | 27.1% |
| 2017 | CNY 101M | 0.11 | 15.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jun 6, 2019.
Who owns Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Insiders 70.76%
- Institutions 5.26%
- Public & others 23.99%
- Shares outstanding 921M
- Free float 280M
Chengdu Kanghong Pharmaceuticals Group Co Ltd company profile
- Company name
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Ticker
- 002773.SHE
- ISIN
- CNE1000020C4
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,470
- Fiscal year end
- December
- Address
- No 108, Shuxi Road, Chengdu, China, 610037
- Phone
- 86 28 8750 2055
- Website
- cnkh.com
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices in China. It develops medicines for ophthalmic, neuropsychiatric, and others. The company was founded in 1996 and is headquartered in Chengdu, China.
Chengdu Kanghong Pharmaceuticals Group Co Ltd management
8- Mr. Xiao KeGM, President & Director · born 1983
- Mr. Jian Jun ZhongCFO & VP · born 1967
- Mr. Jin Qun YinVP & Director · born 1972
- Ms. Jian Rong ZhongVP & Director · born 1957
- Mr. Kang DengBoard Secretary & Assistant to the President · born 1981
- Ms. Yanhua XuVice President · born 1973
- Ying Mei HeChief Accounting Officer
- Zhigang JiangSponsor Representative